Which Is a Better Investment, Veracyte, Inc. or Xencor, Inc. Stock?
Learn more about whether Veracyte, Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Commentary & Analysis
Which Is a Better Investment, CareDx, Inc. or Veracyte, Inc. Stock?
Learn more about whether CareDx, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Why Veracyte, Inc.’s (VCYT) Stock Is Down 19.99%
As of Friday, July 31, Veracyte, Inc.’s VCYT share price has dipped by 19.99%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Veracyte, Inc.’s (VCYT) Stock Is Down 23.51%
As of Friday, July 31, Veracyte, Inc.’s VCYT share price has dipped by 23.51%, which has investors questioning if this is right time to buy.Jenna Brashear
Is Veracyte, Inc. (VCYT) Overvalued?
We dive into why Veracyte, Inc. (VCYT) could be considered overvalued on 2026-07-30, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | VCYT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,359.5 | $286.3 | 61% |
|
| Shares Out (Mil) | 82.1 | 54.2 | 58% |
|
| Institutional Ownership | 99.5% | 92.8% | 89% |
|
| Float (Mil) | 79.9 | 39.7 | 57% |
|
| Beta | 1.94 | 0.94 | 92% |
|
| Avg Daily Volume (000s) | 1,159 | 534 | 73% |
|
| Price Change (52-week) |
41.3% | 58.7% | 75% |
|
| Growth | VCYT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 34.5% | 13.6% | 92% |
|
| Net Income (5yr) | 31.3% | (10.1%) | 86% |
|
| EPS (5yr) | 26.6% | 16.0% | 77 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.2%) | (15.6%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | $0.413 | $1.906 | $1.948 | |
| Month Ago EPS | $0.437 | $1.804 | $1.887 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.434 | $1.824 | $1.905 | |
| Year/Year Chg | 33.2% | 132.4% | 151.8% | |
| Financials | VCYT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $562 | $37 | 42% |
|
| Net Income (TTM) (Mil) | $115 | ($43) | 62% |
|
| EPS (TTM) | $1.443 | ($1.400) | 66% |
|
| Operating Cash Flow (TTM) (Mil) | $178 | ($31) | 58% |
|
| Net Cash Flow (TTM) (Mil) | $80 | $2 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $34 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | $3,279 | $160 | 56% |
|
| Valuation | VCYT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.42 | 2.77 | 57% |
|
| P/E | 30.0 | 19.1 | 69% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.1 | 1.0 | 49% |
|
| Ratios | VCYT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 73.8% | 64.2% | 84% |
|
| Net Margin | 20.4% | (75.9%) | 79% |
|
| ROA | 8.1% | (47.3%) | 83% |
|
| ROE | 8.8% | (55.0%) | 54% |
|
| Liabilities to Assets | 6.6% | 29.6% | 3% |
|
| F-Score | 8 | 2 | 93% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
FACTOR STRATEGY
Return on Equity Screen
Factors: Quality, Growth
A screen that identifies stocks with above average earnings and sales growth that have consistently outperformed their peers measured by ROE.
| Performance Since Inception: | 13.1% |
| +/- S&P 500: | +5.6 |
